Xuan Zhang

Xuan Zhang

Auto-generated profile, based on publicly available information

Xuan Zhang

Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
XZXuan Zhang
Xuan Zhang
BSBaobao Song
Baobao Song
MCMaximillian J. Carlino
Maximillian J. Carlino
GLGuangyuan Li
Guangyuan Li
KFKyle Ferchen
Kyle Ferchen
HGH. Leighton Grimes
H. Leighton Grimes
Analysis of the human hematopoietic progenitor compartment is being transformed by single-cell multimodal approaches. Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) enables coupled surface protein and transcriptome profiling, thereby revealing genomic programs underlying progenitor states. To perform CITE-seq systematically on primary human bone marrow cells, we used titrations with 266 CITE-seq antibodies (antibody-derived tags) and machine learning to optimize a panel of 132 antibodies. Multimodal analysis resolved >80 stem, progenitor, immune, stromal and transitional cells defined by distinctive surface markers and transcriptomes. This dataset enables flow cytometry solutions for in silico-predicted cell states and identifies dozens of cell surface markers consistently detected across donors spanning race and sex. Finally, aligning annotations from this atlas, we nominate normal marrow equivalents for acute myeloid leukemia stem cell populations that differ in clinical response. This atlas serves as an advanced digital resource for hematopoietic progenitor analyses in human health and disease.

17 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
GLGuangyuan Li
Guangyuan Li
SMShweta Mahajan
Shweta Mahajan
SMSiyuan Ma
Siyuan Ma
EJErin D. Jeffery
Erin D. Jeffery
XZXuan Zhang
Xuan Zhang
NSNathan Salomonis
Nathan Salomonis
Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a patient’s own immune system. Although immunotherapy is typically reserved for patients with a high mutational burden, neoantigens produced from posttranscriptional regulation may provide an untapped reservoir of common immunogenic targets for new targeted therapies. To comprehensively define tumor-specific and likely immunogenic neoantigens from patient RNA-Seq, we developed Splicing Neo Antigen Finder (SNAF), an easy-to-use and open-source computational workflow to predict splicing-derived immunogenic MHC-bound peptides (T cell antigen) and unannotated transmembrane proteins with altered extracellular epitopes (B cell antigen). This workflow uses a highly accurate deep learning strategy for immunogenicity prediction (DeepImmuno) in conjunction with new algorithms to rank the tumor specificity of neoantigens (BayesTS) and to predict regulators of mis-splicing (RNA-SPRINT). T cell antigens from SNAF were frequently evidenced as HLA-presented peptides from mass spectrometry (MS) and predict response to immunotherapy in melanoma. Splicing neoantigen burden was attributed to coordinated splicing factor dysregulation. Shared splicing neoantigens were found in up to 90% of patients with melanoma, correlated to overall survival in multiple cancer cohorts, induced T cell reactivity, and were characterized by distinct cells of origin and amino acid preferences. In addition to T cell neoantigens, our B cell focused pipeline (SNAF-B) identified a new class of tumor-specific extracellular neoepitopes, which we termed ExNeoEpitopes. ExNeoEpitope full-length mRNA predictions were tumor specific and were validated using long-read isoform sequencing and in vitro transmembrane localization assays. Therefore, our systematic identification of splicing neoantigens revealed potential shared targets for therapy in heterogeneous cancers.

6 June 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
XZXuan Zhang
Xuan Zhang
CBChengfeng Bi
Chengfeng Bi
TLTing Lu
Ting Lu
WZWeiwei Zhang
Weiwei Zhang
TYTing Yue
Ting Yue
KFKai Fu
Kai Fu

19 January 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
CBChengfeng Bi
Chengfeng Bi
XZXuan Zhang
Xuan Zhang
TLTing Lu
Ting Lu
XZXiaoyan Zhang
Xiaoyan Zhang
XWXianhuo Wang
Xianhuo Wang
KFKai Fu
Kai Fu
Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clinical treatment of aggressive B-cell lymphoma.

15 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WZWeiwei Zhang
Weiwei Zhang
CWCheng Wang
Cheng Wang
XZXuan Zhang
Xuan Zhang
With the development of technology, an enormous amount of sequencing data is being generated rapidly. However, transforming this data into patient care is a critical challenge. There are two difficulties: how to integrate functional information into mutation interpretation and how to make the integration easy to apply. One solution is to visualize amino acid changes with protein structure and function in web app platform. There are multiple existing tools for plotting mutations, but the majority of them requires programming skills that are not common background for clinicians or researchers. Furthermore, the recurrent mutations are the focus and the recurrence cutoff varies. Yet, none of the current software offers customer-defined cutoff. Thus, we developed this user-friendly web-based tool, Mutplot (https://bioinformaticstools.shinyapps.io/lollipop/). Mutplot retrieves up-to-date domain information from the protein resource UniProt (https://www.uniprot.org/), integrates the submitted mutation information and produces lollipop diagrams with annotations and highlighted candidates. It offers flexible output options. For data that follows security standards, the app can also be hosted in web servers inside a firewall or computers without internet with Uniprot database stored on them. Altogether, Mutplot is an excellent tool for visualizing protein mutations, especially for clinicians or researchers without any bioinformatics background.

21 November 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
NBNeil Beeharry
Neil Beeharry
SLSean Landrette
Sean Landrette
SGSophia Gayle
Sophia Gayle
MHMarylens Hernandez
Marylens Hernandez
JGJeff E. Grotzke
Jeff E. Grotzke
HLHenri Lichenstein
Henri Lichenstein
Key Points: The heat shock protein 90 inhibitor LAM-003 displays potent in vitro and in vivo activity as a single agent and combined with venetoclax. LAM-003 retains antileukemic activity against AML cells rendered resistant to FLT3 kinase inhibitors by mutation or stromal signaling.